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Twitter summary: There is a small risk of cross infection with Pseudomonas aeruginosa in bronchiectasis, 
but the benefit of specialised clinics, chest physiotherapy and pulmonary rehabilitation outweigh 
theoretical risks.  
 
 
 
 
 
 
 
 
 
 
  
 
  
Involving patients in the design, conduct and dissemination of clinical research, clinical guidelines and 
education projects is highly beneficial, and is a priority for funders and societies including the European 
Respiratory Society (ERS).(1) Bronchiectasis is a lung condition associated with chronic cough and 
sputum production that is rapidly increasing in prevalence in Europe.(2) It is a neglected disease, but 
recent initiatives including the European Bronchiectasis Registry and research network (EMBARC) and 
the European Union supported European Reference Network for Rare Pulmonary Diseases (ERN-LUNG) 
are beginning to raise the diseases profile and stimulate new research.(3,4) Patient involvement has 
been, and remains, central to these projects including the recently published European Bronchiectasis 
Guidelines which were developed with patients as members of the panel.(5) 
 
Patient with bronchiectasis are frequently chronically infected with bacterial pathogens.(6) Recent 
publications have raised the concern that bacteria such as Pseudomonas aeruginosa could be 
transmitted between patients (cross-infection).(7-10) EMBARC, ERN-Lung and ELF activities in 
bronchiectasis involve face-to-face meetings involving multiple patients, and the recent ERS guidelines 
recommended that bronchiectasis patients should be involved in group activities such as pulmonary 
rehabilitation where they may come into contact with other patients.(5) Consequently we conducted a 
review of the risk of potential transmission of pathogens in bronchiectasis in order to guide international 
bronchiectasis patient activities.  
 
Recommendations in cystic fibrosis 
The risk of cross-infection with pathogens such as Pseudomonas aeruginosa, Methicillin Resistant 
Staphylococcus aureus (MRSA) and Burkholderia cepacia complex, and most recently Mycobacterium 
abscessus is a matter of concern in patients with cystic fibrosis bronchiectasis (CF). (11-16) 
As a result of compelling evidence of transmission of these organisms between people with CF and, in 
the case of Burkholderia cepacia complex organisms and  P. aeruginosa, the identification of 
transmissible “epidemic” strains, clear guidance has been published which recommends restrictions on 
contact between CF patients. (15,16) These guidelines recommend that universal precautions should be 
taken with individuals with CF and clinics should be cohorted, separating patients with B. cepacia 
complex infection, P. aeruginosa and other infections. All direct contact whether inside or out of the 
hospital between individuals with CF should be avoided(15,16) CF physicians are also advised to practice 
rigorous hand hygiene and other measures since microorganisms can survive on surfaces, hands or 
clothing for several hours.(14,17) For patient support events and conferences, participation by CF 
patients is heavily restricted. The CF Trust in the UK limits participation strictly to a single CF patient for 
indoor events and has strict regulations for outdoor events. Virtually all international guidelines for CF 
advocate similar measures to reduce the risk of cross-infection.(15,16) These are clearly 
recommendations that individuals with CF may choose not to adhere to, or may be unable to adhere to, 
for example where patients are siblings. For institutional events and in healthcare facilities, however, 
the principal of restricting access to minimise exposure to other people with CF is very important widely 
implemented.  
 
Cross-infection in bronchiectasis 
Cross infection, particularly with P. aeruginosa is also a potential concern in bronchiectasis not due to CF 
because of evidence that P. aeruginosa infection is associated with an increased risk of death, 
exacerbation and worse quality of life.(18) The ERS bronchiectasis guidelines did not address the issue of 
cross-infection.(5) This reflects the lack of evidence, which prevents recommendations being made in an 
evidence based guideline. Of note, the current Spanish Society of Pneumology and Thoracic Surgery 
(SEPAR), the British Thoracic Society and guidelines from Australia and New Zealand also make no 
specific recommendations regarding the risk of cross-infection.(19-21) The ERS guidelines do, however, 
emphasise the importance of specialised care for the management of bronchiectasis, which is best 
delivered within specialised centres seeing a large number of patients and recommend that patients 
with bronchiectasis and significant breathlessness attend pulmonary rehabilitation.(5, 22-25) Pulmonary 
rehabilitation and specialist outpatient clinics are environments where patients with bronchiectasis will 
inevitably come into contact with other patients with a theoretical risk for cross-infectino with 
respiratory pathogens.   
 
What is the evidence for the risk of cross-infection in bronchiectasis? 
Bronchiectasis and CF are two quite distinct conditions, with a different spectrum of microbiology and a 
different pathophysiology.(26) B. cepacia complex, the most feared transmissible pathogens in CF, is 
very rarely cultured in bronchiectasis. (22-27) While infection with P. aeruginosa is almost universal in 
CF over a patient’s lifetime, P. aeruginosa affects only 20% of patients with bronchiectasis in 
Europe.(5,18,23,27). It may be speculated that only a proportion of patients with bronchiectasis are 
susceptible to persistent P. aeruginosa infection which tends to be concentrated in patients with more 
severe and extensive bronchiectasis.(27)  
We conducted a scoping review using Pubmed (using search terms “cross-infection” OR “transmission” 
AND “bronchiectasis”, supplemented by searches of American Thoracic Society, ERS, BTS and World 
Bronchiectasis Conference abstracts 2014-2017. Searches were limited to articles in English only and no 
date limits were applied). Any article type was accepted including case reports and case series. The 
primary search identified 117 articles, and an additional 8 abstracts and 4 papers were identified as 
potentially relevant in supplementary searches. Review of the full manuscripts/abstracts excluded 123 
articles/abstracts that did not report on cross-infection leaving 6 potentially relevant articles. These are 
discussed below.   
Based on this literature review, reports of cross-infection in bronchiectasis to date are extremely rare. 
Acquisition of a multidrug resistant strain of P. aeruginosa in a fourteen-year old boy with bronchiectasis 
due to chronic aspiration was reported by Robinson et al in 2003.(28) The patient had shared 
accommodation and physiotherapy facilities with a CF patient harbouring a genetically identical strain 
making transmission likely.(28) In contrast, a study of 64 P. aeruginosa isolates from 16 patients with 
bronchiectasis in Spain found no evidence of cross-infection, based on the high degree of genetic 
dissimilarity between each isolate.(29)  
De Soyza and colleagues performed a single centre study of 56 isolates and 36 bronchiectasis 
patients.(7) They identified that the vast majority of P. aeruginosa isolates appeared to be acquired from 
the environment but could not exclude cross-infection in two cases. Genetic similarity between strains 
does not prove cross-infection, since acquisition from a common environmental source is also 
possible.(7) A lack of longitudinal “before and after” data also means we do not know if these strains 
represented a new infection by P. aeruginosa, or acquisition of a new strain among many in a patient 
already infected with P. aeruginosa. It is also not known whether any acquisition is associated with a 
clinical deterioration.(7) 
Most recently Hilliam et al performed a multi-centre study using whole genome sequencing of 189 
isolates from 91 patients attending 16 UK bronchiectasis centres.(8) In this study there were 5 examples 
of strains from different patients that were genetically similar but again did not have the 
epidemiological or longitudinal data to prove transmission vs common source acquisition. The authors 
concluded that there was no evidence to suggest a widespread transmissible strain in the UK 
bronchiectasis community, and that the P. aeruginosa lineages that are common in bronchiectasis are 
generally those that are also highly abundant in the environment.(8) In a study reported in abstract form 
only, variable number tandem repeat (VNTR) typing was used on 144 isolates from 84 patients with 
bronchiectasis.(9) This study identified 3 cases of bronchiectasis patients infected with epidemic strains 
apparently acquired from CF patients during inpatient stays.(9) No evidence of transmission from 
bronchiectasis patients to other bronchiectasis patients was identified. A recently published cohort 
study from the UK identified 3 patients sharing strains likely to have been acquired through cross-
infection.(10) All three patients were known to be chronically infected with P. aeruginosa prior to the 
presumed acquisition event.(10) Based on the apparently infrequent nature of transmission, the authors 
of this study did not advocate a change in infection control policy.(10)  
 
Interpretation 
The above review identifies that cross-infection with P. aeruginosa has occurred in bronchiectasis 
patients but that  
1- Such events are rare, and there is so far insufficient evidence to establish if new acquisition of P. 
aeruginosa infection (vs. acquisition of new strains in patients already infected with P. 
aeruginosa) has occurred. 
2- There is insufficient evidence to show that cross-infection is associated with clinical 
deterioration. 
3- Epidemic and highly transmissible strains have not been identified in the bronchiectasis 
population, except in one study where these were shown to be likely acquired from CF patients. 
4- The strongest evidence for transmission overall and transmission of multidrug resistant or highly 
virulent strains in particular appears to be from CF patients to bronchiectasis patients, rather 
than within the bronchiectasis population. EMBARC data suggests that 10% of bronchiectasis 
patients in Europe are managed in CF clinics, while 45% are managed in centres with shared 
facilities for CF patients.(30)  
5- The current studies are inadequate in terms of numbers of patients and availability of clinical 
data and longitudinal follow-up. There are no studies addressing cross-infection with 
Staphylococcus aureus, MRSA, NTM or less common organisms in bronchiectasis.  
 
Patient perspective 
The EMBARC/ELF patient advisory group discussed this issue with a panel of clinicians at the 2nd World 
Bronchiectasis Conference in Milan, facilitated by the ELF. The discussions revealed that patients have 
diverse views on the importance of cross-infection. Patients infected with organisms such as P. 
aeruginosa or S. aureus are concerned about the risk of transmitting this to other patients or indeed to 
immunosuppressed patients and would value guidance on how to reduce any such risk. The majority of 
patients regarded the risk of acquiring new organisms from other patients as small, and an acceptable 
risk if the alternative is a lack of availability of peer support, specialised clinics and services such as 
pulmonary rehabilitation. The majority of patients thought they had a right to know about the risks so 
that they could make an informed decision about, for example, attending patient support group events. 
Many patients expressed concern that their condition would be stigmatised if they are required to wear 
masks or are unable to be in contact with others. In general, patients expressed frustration that 
infection control measures are often neglected in terms of their general management. Exacerbations 
resulting from exposure to relatives, members of the public or other patients with viral infections is a 
more frequent and regular problem for patients, and measures to avoid acquiring such infections are 
rarely discussed with patients.  
 
Working group consensus 
In the absence of high quality evidence, it is not possible to make strong recommendations about 
current practice with regard to infection control in patients with bronchiectasis. Nevertheless, clinicians 
need to make decisions about how to manage this issue in their clinics, while EMBARC, ERN-Lung and 
ELF must develop policies on how to manage any potential risk during patient meetings and events. The 
following represents a pragmatic consensus developed by the panel in response to these issues.  
 
First, in relation to possible transmission from individuals with CF to individuals with bronchiectasis, 
detailed guidelines on infection control in patients with CF are already available from relevant national 
and international societies.(15,16,31) Where bronchiectasis patients are managed within a CF service we 
suggest managing these patients according to the same strict infection control procedures as patients 
with CF. This would suggest that patients with bronchiectasis should avoid sharing outpatient waiting 
rooms, clinic rooms or hospital bays with patients with CF. For the purposes of patient support group 
meetings, congresses or other events, patients with bronchiectasis should not have direct contact with 
individuals with CF. 
 
Within bronchiectasis clinics, a balance must be found between the theoretical risk of cross-infection, 
and the risk of adversely impacting patient care. Patients with bronchiectasis benefit from specialist care 
in centres that see a large number of patients. Cohorting patients by organism is likely to be impractical 
in many hospitals in the absence of specific funding for this. Cohorting is also difficult to justify since our 
review did not identify a single confirmed case of new infection with P. aeruginosa acquired from a 
fellow patient with bronchiectasis. It is our judgement that there is currently not sufficient evidence to 
recommend separation of bronchiectasis patients with P. aeruginosa infection. Similarly, there are clear 
benefits of pulmonary rehabilitation with the evidence demonstrating improved exercise capacity, 
improved quality of life and reduced exacerbations.(5) These benefits outweigh the theoretical risk that 
attending a pulmonary rehabilitation class with other patients could expose the patient to the risk of 
transmission of a microorganism. Care for bronchiectasis in Europe is currently heterogeneous and 
predominantly inadequate with data suggesting most patients do not receive what may be regarded as 
the basic components of bronchiectasis care, such as chest physiotherapy, sputum culture, antibiotic 
therapy and self-management.(32) In this context, precious resources should be directed at improving 
basic medical management.  
In the event of suspected transmission or a suspected outbreak we recommend seeking expert 
microbiological help and that facilities to investigate potential outbreaks using molecular methods 
should be made available.  
We recommend that discussing the topic of infection control, including avoiding infections as well as the 
risk of transmission should be part of the bronchiectasis clinic consultation for all patients.  
For patient support groups, research initiatives and social events, the balance of risks and benefits must 
be carefully weighed on a case-by-case basis. The value to patients of participation in such events is 
clear, and the need for advocacy and support in a disease like bronchiectasis is acute. Therefore, in the 
absence of evidence of harm, we do not currently advocate preventing patients from participating in 
such activities. We nevertheless have adopted the following recommendations for EMBARC/ELF events: 
 Patients should be informed that contact with other patients may carry a risk of transmission of 
infection. This allows patients to make an informed decision about whether to participate in such 
events. 
 All participants at such events should practice rigorous hand hygiene measures and patients 
should aim to minimise the production of potentially infectious aerosols by conduct chest clearance 
at home prior to attending and by covering their mouth while coughing.  
 Since shaking of hands is known to be a primary source of pathogen transmission in other areas, 
hand shaking at events or in hospital is discouraged. 
 Venues should have adequate space and ventilation. 
 Basic infection control measures to reduce close contact between patients should be practiced 
e.g avoid sharing food/drinks/mobile phones and avoid activities promoting close physical contact.  
 Patients should not attend events with other patients if they are unwell, or have a current 
exacerbation. 
 We suggest that of patients who may be at higher risk of cross-infection e.g 
immunocompromised patients, or patients with multidrug resistant organisms should seek advice 
from their care team about the advisability of attending events.   
 Use of electronic or virtual means of communication (teleconferences, webinars etc) should be 
considered where available.  
 
Patients are also concerned to reduce their risk of exacerbation by reducing the acquisition of viral and 
other infections. We identified no evidence that infection control measures can prevent exacerbations. 
We therefore suggest that patients are advised to practice standard hygiene measures, such as hand 
washing before meals and that patients should avoid contact where possible with children and adults 
with active viral infections. Patients should be encouraged to receive influenza and other vaccinations in 
line with national recommendations.  It was discussed that some patients in online forums recommend 
face-masks to reduce infection risk in bronchiectasis. The panel recommended against the use of 
facemasks due to a lack of evidence for their effectiveness and the risk of stigmatising bronchiectasis 
patients.  
Finally, the topic of cross-infection is a key research priority in bronchiectasis. Cross-infection was 
identified by both patients and physicians as one of the 55 key research questions in the field of 
bronchiectasis, In the EMBARC “roadmap” published in 2016.(24) We strongly recommend that large 
scale longitudinal studies are performed to ascertain the incidence and clinical implications of cross-
infection in bronchiectasis. 
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